Q Hydrogen Announces Clean Hydrogen Power Plant

Thanks to ECW reader Jag for sending the following:
which in part says

“Clear hydrogen is produced by extracting hydrogen from water, like green hydrogen, but rather than using electrolysis to “zap” the hydrogen away from the oxygen, a new technology does so using water that is subjected to external influences coupled with extremely rapid variations in pressure, temperature and motion. There is no heat, and more importantly, no carbon used or generated in the process.
This allows for hydrogen production at significantly reduced cost, without the carbon impact of conventional methods”

On the website of the company (https://www.qhydrogen.com/about/) there is the further statement which says:
“Our newest commercial implementation in New Hampshire will be the world’s first power plant fueled by clean, economical Q Hydrogen. We will utilize the Q Hydrogen Generator, which will produce sufficient low-cost hydrogen to fuel the facility’s initial generating capacity of around seven megawatts. Someday, up to 100 megawatts may be generated at this facility on a total industrial footprint of approximately five acres”
All that intrigued me but I was not convinced until I looked at their team at https://www.qhydrogen.com/team/
The inventor Whitaker B. Irvin, Sr. has a whole series of patents granted and pending
One among the several top notch advisors is General (R) James T. Hill U.S. Army Retired Four Star General – He also checks out.
To me what it looks like is that this could be very low cost clean energy

Mizuno Technology Announces Move to Commercial Phase

Thanks to David Nygren for posting the following in the Always Open thread.

Mizuno update 2020-11-26

Mizuno Technology, Inc. a Hokkaido based start-up, has now had its cold fusion results replicated independently, and more replications under way. Now we are developing a safe, controllable and powerful reaction to supply nearly unlimited heat to transform poor societies with alternative cooking fuel, heat for agriculture, space heating and clean water. We are moving from the lab to the commercial testing phase. Our mission is to use this technology to improve the lives of the poor and developed countries alike.

Thread on LENR Forum https://www.lenr-forum.com/forum/thread/6017-mizuno-replication-and-materials-only/?postID=147816#post147816

Here is Mizuno’s business website:


Interview: Fusion Researcher Lerner Contends There Was ‘No Big Bang’

Thanks to Gerard McEk for posting a link to an interview from the Asia Times with US physicist and founder of LPP Fusion, Eric Lerner. LPP Fusion is a company which is developing a process of nuclear fusion they call ‘Focus Fusion’ which they describe as a “Dense Plasma Focus device with aneutronic hydrogen-boron fuel”

The interview is dialogue between Eric Lerner and Jonathan Tennenbaum. This link is to the first part of four-part interview titled “The Big Bang Never Happened but Fusion Will.”


Here is a short excerpt from Lerner:

“Saying that the Big Bang theory is a well-confirmed theory is very much like saying that the emperor’s clothes are beautiful. It’s something that lots of people agree on because ultimately their jobs and income depend on it. But it’s not something that’s backed up by scientific evidence.”

“Whenever and wherever you look at what the Big Bang hypothesis predicts, and you compare with observations, then in almost every single case you get a mass of contradictions.”

COVID-19: Press Release “Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study”

The following is a press release from Pfizer and BioNTech SE.

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

  • Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
  • Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
  • Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; safety and additional efficacy data continue to be collected
  • Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
  • Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints

NEW YORK and MAINZ, GERMANY, November 9, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases.

The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continues to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”

“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech Co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from seven days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol at https://www.pfizer.com/science/coronavirus.

Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.

Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced. Based on supply projections, we expect to supply globally up to 50 million vaccine doses in 2020 and manufacture up to 1.3 billion doses in 2021. Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.